Peptide Therapeutics Market By Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Phase Peptide Synthesis (HPPS)), By Delivery Route (Oral Route, Parenteral Route, Pulmonary Route, Mucosal Route), By Applications (Cancer, Cardiovascular Diseases, Metabolic Diseases, Central Nervous System, Infectious Diseases, Gastrointestinal Diseases, Renal Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

This report on global peptide therapeutics market studies various type of application, delivery route, technology and geography. The advantages of using peptide-based molecules for treatment comprises low toxicity, excellent target specificity, high potency, good tolerance, and low incidence of side-effects. The disadvantages of peptide therapeutics are associated with their lack of oral bioavailability due to poor absorption across membrane, imposing parenteral injection as the normal mode of administration which leads to patient inconvenience and discomfort, and to non-compliance. In case competitive scenario of peptide therapeutics market, small biotech companies have seemed to be focusing on a single product or technology, while big pharmaceutical companies possess a diverse portfolio based on therapeutic areas and stresses on collaborations, mergers and acquisitions (M&A), and licensing.

For the purpose of this study, the various types of applications considered are cancer, cardiovascular diseases, metabolic diseases, central nervous system disorders, respiratory diseases, infectious diseases, gastrointestinal diseases, renal disorders, and others (pain management, dermatological disorders, and hematological disorders). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The market segmentation on the basis types of delivery route comprises sub-segments such as oral route, parenteral route, pulmonary route, mucosal route, and other routes (intradermal & nasal). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The market segmentation on the basis types of technology includes sub-segments such as solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid phase peptide synthesis (HPPS). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The geographic segmentation of the global peptide therapeutics market includes regions such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The key players covered in peptide therapeutics market are Amgen Inc., Amylin Pharmaceuticals LLC (Bristol- Myers Squibb), AstraZeneca plc, Bachem Holding AG, Eli Lilly and Company, GlaxoSmithKline plc, Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo- Nordisk A/S, Peptisyntha, PolyPeptide Group, Pfizer, Inc., F. Hoffman-La Roche AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals.

Based on the type of applications, the peptide therapeutics market is segmented into:

  • Cancer
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Central nervous System Disorders
  • Respiratory Diseases
  • Infectious Diseases
  • Gastrointestinal Diseases
  • Renal Disorders
  • Others (Pain Management, Dermatological Disorders, and Hematological Disorders)

In 2015, cancer segment accounted of the major market share due to rising prevalence of cancers coupled with high disease diagnosis rate, rising public awareness associated with the peptide therapeutics and developing overall healthcare infrastructure and supportive government policies. It was also observed that, naturally occurring peptides are most of the times not directly suitable for its application as convenient therapeutics due to factors such as intrinsic weaknesses, a short circulating plasma half-life, and poor chemical and physical stability. The key disease areas presently driving the therapeutic applications of peptide drugs are oncology and metabolic diseases. The factors aiding epidemic growth of metabolic diseases are both obesity and T2DM, in case of oncology by rising mortality and need for chemotherapy replacement along with cancer supportive care. The application of peptide therapeutics in the treatment of diabetes and obesity is possibly the reason behind largest share of North America in the global peptide drug market, with the Asia-Pacific reflecting the largest growth. However, a current trend observed recently was shifted focus of companies towards the infectious diseases and inflammation or pain management, where several peptides are undergoing clinical testing.

Peptide Therapeutics Market

For the purpose of this study, the global peptide therapeutics market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Peptide Therapeutics Market

North America was observed as the largest market in peptide therapeutics industry due to factors such as high awareness associated with therapeutic treatment developments in public, high acceptance for novel products and technologies from patients and medical practitioners, and high healthcare costs. The European peptide therapeutics market has also projected noticeable growth due to factors such as increasing research and development activities associated with peptide therapeutics, and major merger and acquisitions were observed in Europe peptide therapeutics industry. In addition, the major factor that has fueled the research and development activity in Europe peptide therapeutics industry are rising obesity cases and high prevalence of cardiovascular disorders. In Asia-Pacific excluding Japan other countries are at a nascent stage as compared to the more mature markets of North America and Europe. However, countries such as China, Australia and New Zealand are anticipated to be the largest markets for peptide therapeutics and collectively accounted for 78.4% revenue share in year 2015 of the total Asia-Pacific market (except Japan).

Choose License Type
Published Date:  Feb 2017
Category:  Pharmaceuticals
Report ID:   58361
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Connect With Us
+1-408-641-3282
24/7 Research Support